A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Status:
Recruiting
Trial end date:
2028-05-31
Target enrollment:
Participant gender:
Summary
This clinical trial is studying advanced or metastatic solid tumors. Once a solid tumor has
grown very large in one spot or has spread to other places in the body, it is called advanced
or metastatic cancer. Participants in this study must have head and neck squamous cell
cancer, non-small cell lung cancer, endometrial cancer, or ovarian cancer. Participants must
have tumors that have a marker called HER2.
This clinical trial uses an experimental drug called disitamab vedotin (DV). DV is a type of
antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. In
this study, all participants will get DV once every 2 weeks.
This study is being done to see if DV works to treat different types of solid tumors that
express HER2. It will also test how safe the drug is for participants. This trial will also
study what side effects happen when participants get the drug. A side effect is anything a
drug does to your body besides treating the disease.